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INTRODUCTION
Diabetes and the associated hyperglycemic state with advanced 
glycation end products circulating the bloodstream puts patients at 
higher risk to develop cardiac, vascular, and neuronal 
complications (1). Methylglyoxal (MG) is found raised in diabetic 
patient’s  plasma and serves as a precursor of advanced glycation 
end products (2). There still is a lack of strategy to mitigate MG’s 
deleterious effects. Urolithin A (URO A) and Urolithin B (URO B) are 
two novel microbiome derived compounds that can be found 
plentiful in such sources as pomegranates, raspberries, and 
strawberries (3). They are derived from ellagitannins by the gut 
bacteria (4). URO A was recently found to induce a molecular 
signature of improved mitochondrial and cellular health with 
regular oral intake by humans (5). Furthermore, URO B 
demonstrated the ability to induce muscle hypertrophy in 
damaged tissue and reduce tissue atrophy (6 and 7). Their activity 
against MG induced cellular damage has yet to be investigated. 
This study aims to better understand their activity against MG 
damage.
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Measurement of H9c2 cell viability after MG, MG + URO A, MG + URO B, 
or MG + URO A/ URO B treatment:
H9c2 rat myoblasts were treated with cell medium, or varying concentrations 
of MG (100-1400 μM) and incubated for 24 hours to establish the dose effects 
on H9c2 cell viability. MG (1200 μM) was used to test if URO A or URO B or 
the combination of URO A and URO B would mitigate MG-induced cell 
damage. The H9c2 cells were treated with either MG, or MG + varying 
concentrations of URO A, URO B, or MG + combination of URO A and URO B, 
and incubated for 24 hours. Cell viability was determined by measuring 
absorbance at 450 nm after adding tetrazolium by CCK8 assay (Dojindo 
Molecular Technologies, Inc).
Measurement of H9c2 intracellular ROS production following MG, MG + 
URO A, or MG + URO B treatment after 24 incubation:
H9c2 rat myoblasts were incubated with 25 μM non-fluorescent and cell 
permeable dichlorofluorescein diacetate (DCFDA, Abcam) for 45 minutes. 
After washing off DCFDA with incubation buffer, cells were treated with cell 
medium, MG (1200 μM) alone, MG + URO A (5-50 μM), or MG + URO B (5-50 
μM). During incubation, the fluorescence, excited at 480 nm, was recorded at 
520 nm using a Fluroskan Ascent CF scanner (Thermo Scientific) at, 0 minutes, 
1 hour and 24 hours post-treatment.
Measurement of H9c2 cell membrane stability following control MG 
treatment, control + URO A, or control + URO B at 30 minutes:
H9c2 rat myoblasts were treated with the MG 1200 μM alone, or MG with 
URO A (5-50 μM) or URO B (5-50 μM) for 24 hours. Thereafter, Calcein-AM 
and Propidium Iodide solution were added to cells per assay instructions 
(Sigma-Aldrich, Inc.). After another 30-minute incubation, the fluorescence 
excited at 488 nm for Calcein-AM and 530 nm for Propidium Iodide were 
recorded to stain for living and dead cells, respectively.
Statistical Analysis:
All experiments were performed in triplicate and repeated at least three times 
throughout the study duration. All values are presented as a mean ratio ± SE. 
Data were analyzed using ANOVA. Values of p < 0.05 were considered 
statistically significant.
Figure 3: URO A or URO B dose-dependently mitigated MG-induced cell damage. URO A 
and URO B dose dependently improved cell viability when compared to MG (p<0.05). 
Moreover, URO A showed significantly better protection than URO B at all tested doses, 
best performing at URO A 50 µM (1.75±0.5, n = 10, p < 0.05).
Figure 4. Rat myoblast H9c2 cellular viability measured by CCK assay when treated with MG, MG + 
combination of URO A and URO B. The various combinations of the two compounds provided statistically 
significant improvement in cellular viability (p < 0.05). The combinations of URO A 10 µM + URO B 5 µM 
performed best (1.64±0.3, n = 8, p < 0.05), with the second-best combination being URO A 10 µM + URO B 10 
µM (1.39±0.2, n = 8, p <0.05). This assay was done to look for a potential synergistic relationship between the 
two compound combinations. This data suggests a potential synergistic effect between the two compounds. 
Figure 5: The effects of URO A or URO B on MG-induced ROS increase. DCFDA ROS mean production 
ratio at 24 hours generated by H9c2 cells treated with MG, MG + URO A, or MG + URO B. URO A (5-50 
µM) significantly attenuated ROS production at all concentrations (p < 0.05). URO A performed best at 5 
µM (0.82±0.08) and 10 µM (0.88±0.09) and significantly reduced MG-induced ROS (p < 0.05). URO B 
(5-50 µM) did not significantly reduce ROS production at any concentration (p > 0.05), instead it 
significantly increased ROS production compared to control (p < 0.05)
Figure 7: The comparison of URO A and URO B on MG-induced cell membrane damage. Fluorescence emission at 
488 nm with Calcein-AM staining of MG alone, MG + URO A, or MG + URO B to test for cell membrane integrity at 30 
minutes. URO A (5-50 µM, n = 5) and URO B (5-50 µM, n = 5) both demonstrated statistically significant cell 
membrane stabilization. URO A 25 µM and 50 µM performed best and significantly increased the ratios of Calcein-AM 
fluorescence intensity to 3.18±1.9 and 3.24±1.5 (n = 5, both p < 0.05), respectively. URO B showed less increase of 
Calcein-AM staining with 50 µM (1.67±0.6, n = 5, p < 0.05) and 25 µM (1.26±0.6, n = 5, p < 0.05). URO A was 
superior at maintaining cell membrane integrity compared to URO B.
Figure 8: Fluorescence emission at 530 nm with Propidium iodide staining of MG alone, MG + URO A, or 
MG + URO B to test for cell membrane integrity at 30 minutes. URO A 25 µM and 50 µM reduced 
propidium iodide staining to 0.89±0.1 and 0.79±0.2 (n = 5, both p < 0.05), respectively, when compared to 
MG, whereas URO B at all concentration, URO A 5 µM and URO A 10 µM did not show any significant 
reduction at all concentrations (p > 0.05), suggesting higher levels of dead cells.  URO B data was 
inconsistent with CCK findings, suggesting a potentially different mechanism of action for improved cell 
viability. This warrants further investigation into the compound’s activity.
Figure 1: Chemical structures of URO A (left panel) and URO B (right panel).
Figure 6: DCFDA ROS mean production ratio at 0 minutes, 60 minutes, and 24 hours generated by 
H9c2 cells treated with MG, MG + URO A, or MG + URO B. URO A (5-50 µM) at all concentrations 
was able to significantly attenuate ROS production after a 1-hour and 24-hour incubation period (p < 
0.05). URO B (5-50 µM) did not significantly reduce ROS production at any concentration (p > 0.05). 
From here, we can see that drug had slow effects. Similarly, MG also needs time to increase ROS. 
Figure 2: Dose dependent cell viability of various MG concentrations. MG 
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